Category: News & Comments
Senator Sanders and Ariad
Shares of Ariad Pharmaceuticals declined following Senator Bernie Sanders’ criticism of the high price of the firm’s drug Iclusig (ponatinib) on Twitter. Ariad said, "our pricing reflects our significant investment in R&D, our commitment to the very small, ultra orphan...
Read More
October 17, 2016
0
Why We Are Ignoring the Temporary Selling of NKTR. See Also: Agenus Adjuvant in GSK Successful Shingles Vaccine
There is nothing wrong with Nektar Therapeutics (NKTR) . The stock is temporarily underperforming as traders are practicing their conviction that they must sell when a firm finances through dilution. The traders practice this law of thumb regardless of whether...
Read More
October 19, 2016
0
Cytokinetics Heart Failure Drug Worked
POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE Data Showed Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function Amgen (AMGN) and Cytokinetics (CYTK) : Data from the expansion phase of...
Read More
October 27, 2015
0
Regeneron and Sanofi Rheumatoid Arthritis Drug is Still Extremely Promising
Regeneron (REGN) and Sanofi informed that the FDA has issued a Complete Response Letter ( CRL ) regarding the Biologics License Application (BLA) for sarilumab. The drug is an investigational interleukin-6 receptor (IL-6R) antibody for adult patients with moderately to...
Read More
October 31, 2016
0
Another Durable Botulinum Toxin with Many Advantages over Botox
Another Durable Botulinum Toxin with Many Advantages REVANCE THERAPEUTICS As per its self- described profile, Revance Therapeutics (RVNC) manufactures and develops novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum...
Read More
October 29, 2015
0
Dyax Acquisition and Biocryst Future
- Shire to Acquire Dyax for $5.9million and some possible extras. - Angioedema market has treatments for attacks, but not prophylactic products for the prevention of HAE attacks. - A primary reason for the acquisition, but not the only one,...
Read More
November 3, 2015
0
Incyte is a Great Biotech Firm
To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or...
Read More
November 7, 2015
0
Xoma: Good News for the Firm We Love and Hate But We Never Divorce
XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes - Novo Nordisk acquires exclusive global rights to XMetA program, but for diabetes only, while XOMA retains commercialization rights for rare disease indications - $5.0 million upfront payment....
Read More
December 2, 2015
0
Halozyme PEGPH20 Improves the Efficacy of Halavan in Triple Negative Breast Cancer
Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin Mesylate (HALAVEN®) in Triple Negative Breast Cancer Xenografts " at the 38th Annual San Antonio Breast...
Read More
December 10, 2015
0
BioMarin: What Happened During the FDA Committee Meeting?
In our yesterday’s article asking about how the FDA advisory committee has to vote regarding Biomarin product Kyndrisa (drisapersen) for Duchenne muscular dystrophy. We got the answer yesterday during the meeting that took a much longer time than committees’ meetings usually...
Read More
November 25, 2015
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)